The Latest in Lymphoma & Plasma Cell Disorders

Some mutation testing can be useful at CLL diagnosis

October 5, 2018

Frontline rituximab shows long-term success in indolent lymphoma

October 5, 2018

Will quad therapy become the new standard in myeloma?

October 2, 2018

Lymphoma & Plasma Cell Disorders

B-cell maturation antigen targeted in myeloma trials

October 2, 2018

FDA lifts partial hold on tazemetostat trials

September 30, 2018

FDA authorizes ClonoSEQ to detect MRD in ALL, myeloma

September 29, 2018

Prognostic factors guide mantle cell treatment decisions

September 28, 2018

Lymphoma & Plasma Cell Disorders

CAR T-cell studies dominate ongoing cellular therapy trials

September 26, 2018

Real-world clues for optimal sequencing of CLL novel agents

September 25, 2018

CAR T may have curative potential in Hodgkin lymphoma

September 25, 2018

Lymphoma & Plasma Cell Disorders

Outpatient lenalidomide/rituximab yields long-term MCL remission

September 25, 2018

Lymphoma & Plasma Cell Disorders

FDA approves new drug for CLL/SLL and follicular lymphoma

September 25, 2018

Brentuximab vedotin boosts elderly Hodgkin survival

September 23, 2018

Lymphoma & Plasma Cell Disorders

Researchers propose new acute leukemia subtypes

September 18, 2018

Best practices defined for proton therapy in mediastinal lymphomas

September 18, 2018

Lymphoma & Plasma Cell Disorders